Therapeutic Response

CD30 + and HER2-negative status confers therapeutic sensitivity to Brentuximab vedotin in combination with Carboplatin, Etoposide, and Ifosfamide in patients with Hodgkin Lymphoma.

View API

Statements

Source and description

View API